University of Hawaii
Trial Pipeline
Mobile Health Dietary Intervention for Stroke Survivors With Prediabetes or Type 2 Diabetes
NCT07120334
Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV
NCT06935838
Quit-Smoking Study for Native Hawaiians
NCT07075575
CTNow: A Clinical Trials Education Program for Rural Cancer Patients and Oncology Providers
NCT06237816
'Ai Pono Cooking Demonstrations
NCT06526650
PILI 'Āina Household
NCT06526273
mHealth to Improve Diet Quality Among Early Adolescents in SNAP-Ed in Hawaii
NCT06360367
Natives Engaged in Alzheimers Research - 'Ike Kupuna
NCT05534607
Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis
NCT05369546
The Healthy Diet and Lifestyle Study II
NCT05132686
Improving Quality of Life for Colon Cancer Patients and Their Caregivers
NCT04713007
TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer
NCT03680508
Exercise Post-Diagnosis of Breast Cancer
NCT04013568
Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation
NCT04651166
Preventing Excessive Gestational Weight Gain Via Short Mobile Messages in WIC
NCT04330976
Shape Up! Kids Study
NCT03706612
Online Intervention for ANHPI College Students
NCT02318849
Hawaii Patient Reward And Incentives to Support Empowerment
NCT02123251
Glycemic Response to High Amylose Rice
NCT01685879
Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases
NCT01469585
Partners in Care Diabetes Self-management Intervention
NCT01235429
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
What the Pipeline for University of Hawaii Shows
According to the ClinicalTrials.gov registry, University of Hawaii is linked to 49 US clinical trials across every stage of research activity. Of those, 38 studies are currently recruiting — about 78% of the sponsor's indexed portfolio — and 8 are already marked complete, representing roughly 16% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for University of Hawaii reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 3 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for University of Hawaii is Type 2 Diabetes with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.